GlassScriptPhysician profile
Charrika Kelly
NPI 1114517935
$2,941.32
in general payments reported to CMS, 2019-2025
19 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.60 · 2023: $41.60 · 2024: $845 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.03 | 2024-2025 | |
| Pfizer INC. | $287.56 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.85 | 2024-2025 | Xifaxan |
| Qol Medical, LLC | $246.42 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $238.03 | 2024-2025 | Vemlidy, Livdelzi |
| Janssen Biotech, INC. | $192.10 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $171.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $165.02 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $104.02 | 2025 | |
| Celltrion USA INC. | $79.88 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $78.72 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $48.12 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $44.52 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $26.84 | 2025 | |
| Exact Sciences Corporation | $24.99 | 2023 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.63 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $16.61 | 2023 | Farxiga |
| Novo Nordisk INC | $14.07 | 2025 | Wegovy |
| Genentech USA, INC. | $10.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charrika Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.